OCRFA Founder Sol Schreiber passes away
OCRFA Founder Sol Schreiber passes away
With deep sorrow, Ovarian Cancer Research Alliance mourns the passing of our beloved founder and Chairman Emeritus, Sol Schreiber.
News
OCRFA Research Shows Genetic Subtypes Linked to Increased R...
OCRFA Research Shows Genetic Subtypes Linked to Increased Risk of Ovarian Cancer
(June 9, 2016) A ten year, OCRFA-funded study has revealed the effect that the human leukocyte antigen (HLA) genes, which help regulate the body’s immune system, have on how the body responds to treatment of epithelial ovarian cancer. The scientists report that women with certain types of HLA may have an increased risk of ovarian … Continued
Action Alert: Protect Ovarian Cancer Research Funding at th...
Action Alert: Protect Ovarian Cancer Research Funding at the Department of Defense
Later this week, we’ll be sending out a request for you to take Action to help protect ovarian cancer research funding at the Department of Defense. The Ovarian Cancer Research Program (OCRP) is part of the Congressionally Directed Medical Research Program in the Department of Defense (DoD), and funds innovative and cutting edge ovarian cancer … Continued
Newk's Unites 100 Restaurants to Raise $100,000 for Ov...
Newk's Unites 100 Restaurants to Raise $100,000 for Ovarian Cancer Research
Foodie Fast-Casual Brand Reaches Halfway Point in Its 200-Unit Growth Plan JACKSON, Miss. — Pairing a big moment with a big cause, fast-casual Newk’s Eatery is celebrating its centennial restaurant opening by uniting system-wide to raise $100,000 for ovarian cancer research starting April 4. Each of Newk’s 100 restaurants has committed to raising $1,000, inviting … Continued
Newk's Raises more than $110,000 for OCRFA
Newk's Raises more than $110,000 for OCRFA
When Lori Newcomb first visited her doctor for abdominal pain, the last thing she expected to walk out with was a late-stage ovarian cancer diagnosis. Blindsided and heartbroken by a type of cancer very few recognize or understand, Lori and her husband Chris, Co-founder and CEO of Newk’s Eatery, saw an opportunity to save women’s … Continued
OCRFA Research Helps Explain Resistance to Chemotherapy
OCRFA Research Helps Explain Resistance to Chemotherapy
(May 4, 2016) Research funded in part by an OCRFA research grant to Dr. Weiping Zou at the University of Michigan has shown that the sensitivity and resistance to cancer chemotherapies is not fully explained by genomic mechanisms as it has previously thought. In fact, it may be affected by effector T cells (cells that defend … Continued
Stand Up To Cancer Supports “Innovation in Collaboration” i...
Stand Up To Cancer Supports “Innovation in Collaboration” in Cancer Research with $1 Million for Five Teams through Phillip A. Sharp Awards
May 2, 2016 – Stand Up To Cancer (SU2C) has awarded a total of $1 million to five teams of cancer researchers to advance “innovation in collaboration” among SU2C-‐affiliated scientists. Each team, consisting of researchers from different SU2C-‐supported “Dream Teams” or research programs, will receive a grant of $200,000 to support new research projects stemming … Continued
Stand Up To Cancer Supports “Innovation in Collaboration” i...
Stand Up To Cancer Supports “Innovation in Collaboration” in Cancer Research
Stand Up To Cancer Supports “Innovation in Collaboration” in Cancer Research with $1 Million for Five Teams through Phillip A. Sharp Awards May 2, 2016 – Stand Up To Cancer (SU2C) has awarded a total of $1 million to five teams of cancer researchers to advance “innovation in collaboration” among SU2C-affiliated scientists. Each team, consisting … Continued
OCRFA Statement on Results of GOG 252
OCRFA Statement on Results of GOG 252
Many members of the ovarian cancer community have been concerned about the results of GOG 252 clinical trial, which were released last month at the Society of Gynecologic Oncology’s Annual Meeting on Women’s Cancer. OCRFA consulted with a team of our scientific experts, and the consensus of the group is that the results of this … Continued
OCRFA Statement on Results of GOG 252
OCRFA Statement on Results of GOG 252
April 11, 2016 – Many members of the ovarian cancer community have been concerned about the results of GOG 252 clinical trial, which were released last month at the Society of Gynecologic Oncology’s Annual Meeting on Women’s Cancer. OCRFA consulted with a team of our scientific experts, and the consensus of the group is that … Continued
OCRFA Co-authors Paper on Educating about Hereditary Risk A...
OCRFA Co-authors Paper on Educating about Hereditary Risk Across Cancer Types
Ovarian Cancer Research Alliance today announced the online publication of a collaborative best practices paper entitled, “Understanding Hereditary Cancer in the Era of Multi-Gene Panel Testing.” The paper offers key insights into the changing needs of individuals and family members who might be at risk for hereditary cancer. The paper also includes discussion of how … Continued
Q&A with OCRFA Grantee Jill Madden, Ph.D.
Q&A with OCRFA Grantee Jill Madden, Ph.D.
Q&A with Jill Madden, PhD University of Kansas Medical Center Research Institute, Inc. 2016 Ann Schreiber Mentored Investigator Award OCRFA: Tell me about yourself. Did you always want to be a scientist? Were you interested in science as a child? Jill Madden: I grew up on a farm in rural Alden, Iowa, where livestock … Continued